The disease has no cure and, according to Dr. Michael Vogelbaum, chief of neurosurgery and program leader of neuro-oncology at Moffitt Cancer Center in Tampa, Florida, there have been no new drug approvals in the past two decades that have extended the lives of patients with glioblastoma.
The treatment is highly effective for certain blood cancers, but scientists are still studying whether modified versions of CAR-T therapy can be used for solid tumors like glioblastoma.
“We had previous experience using a regular CAR in brain tumors but it wasn’t enough,” said Dr. Marcela Maus, director of the Cellular Immunotherapy Program at the Massachusetts General Cancer Center in Boston.
In Maus’ clinical trial, which included three patients, T-cells were engineered to seek out and attack a protein called EGRF that’s often found in abundance in glioblastoma tumors but is not present in healthy brain tissue.
Maus’ team chose a more targeted approach for their experimental therapy: injecting the cells directly into the cerebrospinal fluid that surrounds the brain and spinal cord.
The biggest takeaway the two newest trials bring to the table, he said, is that CAR-T therapy appears to be able to safely target two proteins commonly found in glioblastoma tumors.
The original article contains 1,492 words, the summary contains 201 words. Saved 87%. I’m a bot and I’m open source!
This is the best summary I could come up with:
The disease has no cure and, according to Dr. Michael Vogelbaum, chief of neurosurgery and program leader of neuro-oncology at Moffitt Cancer Center in Tampa, Florida, there have been no new drug approvals in the past two decades that have extended the lives of patients with glioblastoma.
The treatment is highly effective for certain blood cancers, but scientists are still studying whether modified versions of CAR-T therapy can be used for solid tumors like glioblastoma.
“We had previous experience using a regular CAR in brain tumors but it wasn’t enough,” said Dr. Marcela Maus, director of the Cellular Immunotherapy Program at the Massachusetts General Cancer Center in Boston.
In Maus’ clinical trial, which included three patients, T-cells were engineered to seek out and attack a protein called EGRF that’s often found in abundance in glioblastoma tumors but is not present in healthy brain tissue.
Maus’ team chose a more targeted approach for their experimental therapy: injecting the cells directly into the cerebrospinal fluid that surrounds the brain and spinal cord.
The biggest takeaway the two newest trials bring to the table, he said, is that CAR-T therapy appears to be able to safely target two proteins commonly found in glioblastoma tumors.
The original article contains 1,492 words, the summary contains 201 words. Saved 87%. I’m a bot and I’m open source!